ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Abstract Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transi...

Full description

Saved in:
Bibliographic Details
Main Authors: Simone Meidhof, Simone Brabletz, Waltraut Lehmann, Bogdan‐Tiberius Preca, Kerstin Mock, Manuel Ruh, Julia Schüler, Maria Berthold, Anika Weber, Ulrike Burk, Michael Lübbert, Martin Puhr, Zoran Culig, Ulrich Wellner, Tobias Keck, Peter Bronsert, Simon Küsters, Ulrich T Hopt, Marc P Stemmler, Thomas Brabletz
Format: Article
Language:English
Published: Springer Nature 2015-04-01
Series:EMBO Molecular Medicine
Subjects:
cancer stem cells
drug resistance
HDAC inhibitor
miR‐203
ZEB1
Online Access:https://doi.org/10.15252/emmm.201404396
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201404396

Similar Items